DBD
Diebold Nixdorf, Incorporated
DBD has lower modeled downside risk, despite its lower overall score.
SNDK
Sandisk Corporation
SNDK has the edge over DBD overall, supported by stronger fundamentals and stronger modeled upside.
DBD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Stable |
DBD's profitability is currently healthy, and its revenue, cash flow and balance sheet are stable.
SNDK Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Strong | |
| Strong | |
| Strong |
SNDK's revenue, profitability, cash flow and balance sheet are all currently strong.
DBD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 0.7x | $1.54 | -97% |
| Forward | 9.8x | $54.75 | — |
| Fair | 22x | $44.94 | -18% |
| Current | 26x | $54.75 | — |
| Expensive | 32x | $67.83 | +24% |
Historical ranges are pointers, not guarantees.
DBD's PE is in its fair range at 26x. If earnings grow as analysts expect, today's price would be 9.8x next year's earnings.
SNDK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.8x | $937 | — |
| Current | 7.5x | $937 | — |
| Cheap | 17x | $2,173 | +132% |
| Fair | 24x | $3,048 | +225% |
| Expensive | 59x | $7,452 | +695% |
Historical ranges are pointers, not guarantees.
SNDK has the edge over DBD in the historical PE scenario, which offers more potential upside but is not a forecast.
DBD Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect DBD's earnings to grow and its profitability to improve, with its revenue holding steady.
SNDK Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Moderate | |
| High |
SNDK has the edge over DBD on the outlook, with more favorable revenue expectations.
DBD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $5.56 | +166% |
| Q3 2026 | $2.09 | +53% |
| Q2 2026 | $3.01 | +$3.35 |
| Q1 2026 | $2.90 | +$3.17 |
| Q4 2025 | $2.54 | +$2.98 |
| Q3 2025 | $1.37 | +$1.37 |
| Q2 2025 | -$0.34 | -101% |
| Q1 2025 | -$0.27 | -101% |
| Q4 2024 | -$0.44 | -101% |
DBD's earnings per share have fallen from their peak: $2.09 over the past year, against $57.03 in mid-2024.
SNDK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $247.30 | +97% |
| Q3 2026 | $125.61 | +$137.63 |
| Q2 2026 | $73.76 | +$85.07 |
| Q2 2025 | -$11.31 | -$6.65 |
SNDK has the edge over DBD in the latest year-over-year earnings comparison.
DBD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $994.3M | +5.2% |
| Q2 2026 | $930.8M | +1.7% |
| Q1 2026 | $891.8M | +6% |
| Q4 2025 | $1.1B | +12% |
| Q3 2025 | $945.2M | +2% |
| Q2 2025 | $915.2M | -2.6% |
| Q1 2025 | $841.1M | -6.1% |
| Q4 2024 | $988.9M | -4.6% |
DBD's revenue has grown year over year for five quarters in a row: $994M last quarter, up 5.2% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.9% | -3.9 points |
| Q2 2026 | 6.2% | 0 points |
| Q1 2026 | 3.7% | +0.1 points |
| Q4 2025 | 7.5% | +3.3 points |
| Q3 2025 | 7.8% | +2.8 points |
| Q2 2025 | 6.1% | -1.4 points |
| Q1 2025 | 3.5% | +0.9 points |
| Q4 2024 | 4.2% | -1.2 points |
DBD's operating margin was 3.9% last quarter, down 3.9 points from the same quarter a year ago.
SNDK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $11B | +378% |
| Q2 2026 | $9B | +372% |
| Q1 2026 | $6B | +251% |
| Q4 2025 | $3B | +61% |
| Q3 2025 | $2.3B | +23% |
| Q2 2025 | $1.9B | +8% |
| Q1 2025 | $1.7B | -0.6% |
| Q4 2024 | $1.9B | +13% |
SNDK has the edge over DBD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 80% | +72 points |
| Q2 2026 | 78% | +78 points |
| Q1 2026 | 69% | +180 points |
| Q4 2025 | 35% | +25 points |
| Q3 2025 | 7.6% | -9 points |
| Q2 2025 | 0.9% | N/A |
| Q1 2025 | -111% | -122 points |
| Q4 2024 | 10% | +6.6 points |
SNDK has the edge over DBD on profitability, with a higher operating margin.
DBD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$47.4M | -227% |
| Q2 2026 | -$13.6M | -145% |
| Q1 2026 | $31.7M | +102% |
| Q4 2025 | $217.5M | +11% |
| Q3 2025 | $37.4M | +$52.9M |
| Q2 2025 | $30.1M | +$38.1M |
| Q1 2025 | $15.7M | +$39.2M |
| Q4 2024 | $196.2M | +26% |
DBD has burned cash in most quarters: $188M over the past year, down 33% from the year before.
SNDK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.3B | +1340% |
| Q2 2026 | $7.1B | +14355% |
| Q1 2026 | $3B | +$3B |
| Q3 2025 | $438M | +$636M |
| Q2 2025 | $49M | +$217M |
| Q1 2025 | -$18M | +$23M |
| Q3 2024 | -$198M | -$157M |
SNDK has the edge over DBD on cash flow, with more consistent year-over-year improvement.
DBD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -2% | -700K shares |
| 1 year | -6.5% | -2.4M shares |
| 3 years | -7.9% | -3M shares |
| 5 years | -56% | -43.7M shares |
| Available history | -55% | -42.2M shares |
DBD has the edge over SNDK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $33.9M |
| Q2 2026 | $60.6M |
| Q1 2026 | $60.4M |
| Q4 2025 | $51.1M |
| Q3 2025 | $39.9M |
| Q2 2025 | $30.1M |
| Q1 2025 | $9.6M |
| Q4 2024 | $2.3M |
DBD spent $206M buying back its own shares over the past year, up 152% from the year before.
SNDK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.6% | -1M shares |
| 1 year | +3.4% | +5M shares |
| 3 years | +6.9% | +10M shares |
SNDK has 154M diluted shares, up 3.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $5B |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
DBD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.3x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.5x | Healthy |
| Q4 2025 | 1.5x | Healthy |
| Q3 2025 | 2.2x | Moderate |
| Q2 2025 | 2.5x | Moderate |
| Q1 2025 | 2.7x | Moderate |
| Q4 2024 | 2.8x | Moderate |
DBD's net debt is about 2.3 years of its operating earnings (EBITDA), about the same as a year ago.
SNDK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.4x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
SNDK has the edge over DBD on leverage, with a lower net debt burden relative to earnings.
DBD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 11.4 | Oversold |
DBD's weekly RSI is 35 (neutral) and its Stochastic is 11 (oversold).
SNDK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.2 | Neutral |
| Stochastic | 10.6 | Oversold |
SNDK's weekly RSI is 40 (neutral) and its Stochastic is 11 (oversold).
DBD PE vs Technology Sector
| Metric | DBD | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 28x | 6% below |
| PE % | 61 | 25 | 36 pts above |
DBD is trading at 26x earnings, in line with the Technology sector's median of 28x.
SNDK PE vs Technology Sector
| Metric | SNDK | Sector median | Relative |
|---|---|---|---|
| PE | 7.5x | 28x | 73% below |
| PE % | 4 | 27 | 23 pts below |
SNDK has the edge over DBD on valuation relative to its sector.
DBD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.8 | 11% below |
| 20 week MA | $69.7 | 21% below |
| 50 week MA | $73.3 | 25% below |
| 100 week MA | $62.4 | 12% below |
SNDK has stronger trend alignment. DBD is above 0 of 4 weekly averages versus SNDK above 0 of 3.
SNDK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,317.5 | 29% below |
| 20 week MA | $1,465.4 | 36% below |
| 50 week MA | $1,119.6 | 16% below |
SNDK is in a downtrend: it's below all three of its weekly moving averages, and 16% below its 50-week average.
DBD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $20.1 | $29.0 | +44% |
| 2024 | $29.0 | $42.9 | +48% |
| 2025 | $42.9 | $69.3 | +61% |
| 2026 YTD | $69.3 | $54.8 | -21% |
DBD has finished every year since 2023 higher, and it's down 21% so far in 2026.
SNDK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $50.4 | $250.1 | +396% |
| 2026 YTD | $250.1 | $937.5 | +275% |
SNDK has the edge over DBD on returns for 2026, with the stronger performance.